The tetraspanin CD9 has been shown to interact with different members of the β1 and β3 subfamilies of integrins, regulating through these interactions cell adhesion, migration and signaling. Based on confocal microscopy colocalization and on co-immunoprecipitation results, we report here that CD9 associates with the β2 integrin LFA-1 in different types of leukocytes including T, B and monocytic cells. This association is resistant to stringent solubilization conditions which, together with data from chemical crosslinking, in situ Proximity Ligation Assays and pull-down experiments, suggest a primary/direct type of interaction mediated by the Large Extracellular Loop of the tetraspanin. CD9 exerts inhibitory effects on the adhesive function of LFA-1 and on LFA-1-dependent leukocyte cytotoxic activity. The mechanism responsible for this negative regulation exerted by CD9 on LFA-1 adhesion does not involve changes in the affinity state of this integrin but seems to be related to alterations in its state of aggregation.
Introduction
The β2 subfamily of integrins comprises four distinct members, αLβ2, αMβ2, αXβ2, and αDβ2, that are selectively expressed on leukocytes (for review [15, 28, 33] ). The integrin αLβ2, also termed LFA-1 (Lymphocyte Function-associated Antigen-1) or CD11a/CD18 antigen, is expressed on most types of leukocytes and primarily on lymphocytes, whereas expression of the rest of members of this subfamily is rather restricted to myeloid cells. LFA-1 interacts with intercellular adhesion molecules (ICAM-1, -2, or -3), playing a pivotal role in many crucial leukocyte functions that require intercellular adhesion, such as extravasation into tissues, organization of the immune synapse and antigen presentation, inter-lymphocyte collaboration and killing of target cells by CTL or NK cells [2, 40, 63, 66] .
LFA-1 can exist in different states of activation regarding its ability to bind ligands. Resting T lymphocytes express LFA-1 with low affinity and avidity for ligands, necessary for their normal circulation in the blood as individual cells. However, activation by the TCR-CD3 complex or receptors for different cytokines and chemokines, results in rapid activation of LFA-1 enabling T cells to adhere to other cells [15, 27, 72] . Activation of LFA-1 can be induced through changes in the affinity of individual integrin molecules, reflecting conformational alterations, or through changes in the valency of interactions with multivalent ligands [18] . In terms of ligand binding affinity, at least three different conformational states of LFA-1 have been identified: a bent conformation of low affinity, an extended conformation with closed headpiece displaying intermediate affinity, and a high affinity extended conformation with open headpiece and separated intracellular tails [18, 39] . PMA induces the intermediate affinity state but also increases the diffusion of LFA-1 molecules on the cell surface, which in the presence of multivalent ligand, leads to aggregation/clustering of this integrin [18, 42] . On the other hand, extracellular Mn 2+ induces the high affinity conformation of LFA-1 [18, 26] but also induces changes in the local density (i.e. the Biochimica et Biophysica Acta 1853 (2015) [2464] [2465] [2466] [2467] [2468] [2469] [2470] [2471] [2472] [2473] [2474] [2475] [2476] [2477] [2478] [2479] [2480] clustering) of integrin molecules, which is reflected by changes in the number of effective adhesive bonds (i.e. the valency) with ligand [19, 55] . CD9 is a member of the tetraspanin family of integral membrane proteins [20, 77] abundantly expressed on the surface of endothelial cells, some leukocytes and many types of tumor cells [21, 36, 64] . CD9 was initially characterized as a lympho-hematopoietic marker [14] and received the name "Motility-Regulatory Protein" (MRP) [49] . CD9 has been also implicated in the formation and maintenance of muscular myotubes [68] , in nervous cell neurite outgrowth [61] , and in spermoocyte fusion [23] . Like other tetraspanins, CD9 associates on the cell surface with different integrins and many of the functional effects that have been attributed to CD9 may be indeed related to its ability to associate to integrin molecules [6, 7] .
Functional interactions of CD9 with several members of the β1 and β3 subfamilies of integrins have been reported, usually based on the effects exerted by CD9-specific mAbs on the associated integrindependent adhesion, migration and signaling (reviewed in [6, 7] ). However, to our knowledge, only one published report includes some indication -merely based on co-immunoprecipitation evidencesuggestive of a possible interaction between CD9 and the β2 integrin subunit [69] , although this study did neither address the type or functional aspects of this interaction. In addition, functional association of LFA-1 with tetraspanins CD81 (the most closely related to CD9) and CD82, has been described on T lymphocytes [62, 75] , which prompted us to investigate in more detail whether CD9 is also functionally associated with the β2 integrin LFA-1 on leukocytes.
We report here that CD9 associates directly with LFA-1 in different types of leukocytes and exerts inhibitory effects on its adhesive capacity and on leukocyte LFA-1-dependent cytotoxic activity.
Materials and methods

Cells and cell cultures
Primary T lymphoblasts were obtained from peripheral blood mononuclear cells from healthy donors treated with 5 μg/ml phytohemagglutinin (Amersham Biosciences) for 48 h, as described previously [25, 48] . Cells were then cultured for 7-10 days in RPMI-1640 containing 10% FBS and 50 U/ml IL-2 (Eurocetus). HSB-2 and Jurkat (T cell lines), JY and Daudi (B cell lines) and THP-1 and U937 cells (monocytic cell lines) were cultured in RPMI-1640 supplemented with 10% FBS, antibiotics and glutamine. THP-1 and U937 differentiation into macrophagelike cells was induced with PMA (100 ng/ml) for 24 h.
Expression constructs and RNA silencing transfection
For stable transfection experiments, HSB-2 and U937 cells were electroporated with 20 μg pcDNA3-CD9 plasmid at 200 V (2 × 10 ms pulses in a 0.4 cm electroporation cuvette) using an ECM830 BTX electroporation system and selected with 1 mg/ml G418. For CD9 silencing, Jurkat cells were retroviraly transduced (OriGene Technologies) with the shRNA-coding plasmids TI356235 (the plasmid with the CD9 shRNA cassette insert) and TR20003 ("TR2" control plasmid without shRNA insert), according to manufacturer's indications and selected with 1 μg/ml puromycin.
Antibodies and reagents
ICAM-1-Fc chimeric protein consisting of the five domains of ICAM-1 fused to the Fc region of human IgG1 was prepared as described [9] . Anti-β-tubulin antibody was purchased from Sigma and the anti-CD18 biotin-conjugated antibody (MEM-48) from ImmunoTools. The antibodies anti-β2 integrin Lia3/2 [17] and TS1/18 [58] , anti-αL TP1/40 [17] and TS1/11 [58] , anti-αM Bear-1 [41] and anti-αX HC1/1 [16] , anti-CD9 VJ1/20 [78] , PAINS-10 and PAINS-13 [31] , anti-CD147 VJ1/9 and anti-CD59 VJ1/12 [78] and anti-HSPA8 PAINS-18 [29, 31] were purified by protein A or protein-G affinity chromatography. The anti-CD81 5A6 mAb was kindly provided by Dr. Shoshana Levy (Stanford University School of Medicine, USA), the β2 stimulatory mAb KIM185 by Dr. Martyn K. Robinson (UCB-Celltech., Slough, UK), the anti-CD105 mAb P4A4 by Dr. Carmelo Bernabeu (CIB-CSIC, Madrid, Spain) and the anti-β2 mAb m24 by Dr. Nancy Hogg (Cancer Research UK, London, UK).
Flow cytometry analysis
For protein surface expression analysis cells were washed twice in RPMI-1640, incubated with primary antibodies at 4°C for 30 min, followed by FITC-conjugated anti-mouse IgG (Sigma) and fixed in 2% formaldehyde in PBS. For flow cytometric analysis of m24 epitope expression, HSB-2 and JK cells were washed in cation-free PBS and incubated for 15 min at 37°C with Mn 2+ (10, 20, 40 , 100 and 400 μM) or with Ca 2+ /Mg 2+ (0.5 mM and 1 mM respectively) in the presence of mAb 24 (5 μg/ml), washed and stained with secondary FITC-antimouse IgG. Fluorescence was measured using a FACScanTM flow cytometer (Beckton-Dickinson).
Immunofluorescence, confocal and TIRF microscopy
For immunofluorescence studies cells, treated or not with 0.4 mM Mn 2+ for 20 min at 37°C, were seeded on 12-mm glass coverslips coated with poly-L-lysine (50 μg/ml). Cells were fixed in 2% paraformaldehyde, blocked in 1% BSA in TBS and incubated for 1 h with TS1/11 or TS1/18 mAbs (10 μg/ml), followed by secondary antibody Alexa FluorTM-594 anti-mouse IgG (Invitrogen), rabbit polyclonal anti-CD9 antibody H-110 (Santa Cruz Biotechnology) and Alexa FluorTM-488 anti-rabbit IgG (Invitrogen). For THP-1 cells, Fc receptors were saturated with human gammaglobulin for 30 min, prior to fixation. Samples were mounted with Mowiol reagent (Calbiochem) and images were obtained with a Zeiss LSM510 Meta inverted microscope. Fluorescence colocalization histograms and Pearson coefficient values were obtained using the Fiji plug-in "Intensity correlation analysis" [47, 60] . Fiji software was also used for setting the threshold and for detection and quantitation of fluorescent objects. For TIRF (total internal reflection fluorescence) miscroscopy, JK TR2 and JK shCD9 cells were first activated with PMA (200 ng/ml for 2 h), then plated onto ICAM-1-Fc-coated (14 μg/ml) 35 mm Petri dishes with glass bottom (2.5 × 10 5 cells/plate), and incubated for 90 min at 37°C to allow adhesion. After washing non-adhered cells with PBS, adhered cells were fixed in 2% paraformaldehyde (10 min, room temperature) and then permeabilized with 0.3% Triton-X100 in TBS buffer.
Immunofluorescence staining of beta-2 integrin with mAb TS1/18 was performed as described above, and images were obtained with an inverted Olympus Xcellence IX83P2ZF TIRF miscroscopy system. Fiji software was used for setting the threshold and for detection and quantitation of fluorescence in clusters.
Co-immunoprecipitations
Co-immunoprecipitation experiments were performed using intact cells, in order to detect only surface protein-protein interactions. Cells were incubated for 15 min at 37°C (or for 60 min at 4°C in parallel control experiments) with the specific TS1/18 (anti-β2) or VJ1/20 (anti-CD9) or control anti-CD105 and anti-CD59 antibodies in the presence of 0.5 mM Ca 2+ /1 mM Mg 2+ , followed by washing the antibody excess. Cells were then lysed for 15 min at 4°C in TBS containing 1% Brij-97 or 1% Triton-X100 in the presence of corresponding extracellular cations and protease inhibitors and, after removal of insoluble material, incubated overnight at 4°C with protein G-sepharose. Beads were then washed with 1:5 diluted lysis buffer, boiled in nonreducing Laemmli buffer, resolved by 8% (for β2 detection) or 12% (for CD9) SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were then blocked with 3% BSA and developed with the β2 (MEM-48) or CD9 (VJ1/20) biotin-conjugated antibodies followed by streptavidin HRP (Thermo scientific) and ECL-chemiluminescence.
Covalent chemical cross-linking
THP-1/PMA and JY cells were extracted in 1% Brij97 lysis buffer (containing 20 mM Hepes,150 mM NaCl, 0.5 mM CaCl 2 , 3 mM MgCl 2 and protease inhibitors), pH 7.4. After removal of insoluble material, lysates were treated with 0.25 mM thiol-cleavable cross-linker 3,3′-dithiobis(sulfosuccinimidylpropionate) (DTSSP) for 30 min at 4°C. The cross-linking reaction was quenched for 15 min at room temperature with 10 mM glycine, pH 7.4, and then Triton X-100 was added to a final concentration of 1% (v/v) to cross-linked lysates and to parallel non-cross-linked lysates used as controls. Samples were immunoprecipitated with anti-β2 integrin mAb TS1/18, with anti-CD9 mAb VJ1/20 or with anti-CD9 pAb (H110), as indicated, resolved by SDS-PAGE either under reducing conditions (to break the thiol bond in DTSSP-crosslinked protein complexes) or under non-reducing conditions and subsequent immunoblotting with biotinylated anti-CD9 (VJ1/20) or anti-β2 integrin (MEM-48) mAbs, followed by streptavidin-HRP (Thermo Scientific) and ECL-chemiluminescence.
Pull-down assays
GST-fusion proteins containing the LEL region from human wt CD9, wt CD81 and wt CD63 were prepared as previously described [4, 32, 37] . JY and THP-1 cells were washed three times in PBS and either left untreated or their surface proteins biotinylated with 1 mM EZ-Link R Sulfo-NHS-LC-Biotin (Thermo Scientific) in PBS with 1 mM CaCl 2 , 1 mM MgCl 2 for 30 min at 4°C. Cells were then washed twice in PBS + 100 mM glycine to quench and remove excess biotin. Biotinylated and non-biotinylated cells were lysed in 1% Brij-97 or in 1% Triton-X100 buffer and incubated overnight at 4°C with equal amounts of GST-fusion proteins, pulled down with glutathione-agarose for 3 h at 4°C, washed in 1:10 diluted lysis buffer and boiled in non-reducing Laemmli buffer. For non-biotinylated cells, the presence of β2 integrin in the pulled-down complexes was revealed by immunoblotting with biotinylated mAb MEM-48 and detection with streptavidin-HRP and ECL-chemiluminescence. The levels of pulled-down GST-fusion proteins were assessed by western-blot using an anti-GST rabbit polyclonal antibody (Santa Cruz Biotechnology). For surface-biotinylated cells, all lysate proteins pulled-down by GST or by LEL-GST-CD9 were isolated with glutathione-sepharose beads and detected with streptavidin-HRP and ECL-chemiluminescence.
Cell adhesion assays
Static cell adhesion to ICAM-1-coated dishes was performed as described elsewhere [29, 54] . 96-well flat-bottom plates were pre-coated with 6 μg/ml (for THP-1/PMA and T-lymphoblast cells) or 12 μg/ml (for JY, HSB2 and JK cells) of ICAM-1-Fc and blocked with 1% BSA. For PMAstimulated cell adhesion, cells were incubated with 50 or 200 ng/ml of PMA in RMPI-1640 for 2 h at 37°C. Cells were loaded with the fluorescent probe BCECF-AM (Sigma) and added ( 
Lymphokine-activated killer cell assay
The LAK cell assay was performed essentially as described [30, 53] with 4 × 10 4 Daudi cells/well as targets and 4 × 10 5 T lymphoblasts as effector cells [25] in triplicates in 96-well U-bottom plates in a final volume of 200 μl. For antibody inhibition studies, purified mAbs were used at 50 μg/ml. Then the plates were incubated at 37°C for 5 h and the percentage of specific target cytolysis was determined from the amount of LDH activity, measured as INT reduction, in the culture supernatant. 20 μl of lactate solution (Sigma, 36 mg/ml in 10 mM Tris buffer, pH 8.5) was added to the cell-free supernatant, followed by addition of 20 μl INT solution (Sigma, 2 mg/ml in PBS) and 20 μl of a solution containing NAD + /diaphorase (NAD + : Sigma, 3 mg/ml; diaphorase:
Boehringer, 13.5 U/ml; BSA: 0.03%; sucrose: 1.2%; in PBS) and incubated for 20 min. The reaction was terminated with 20 μl of the LDH inhibitor oxamate (Sigma, 16.6 mg/ml in PBS) and the absorbance at 492 nm was determined in a microplate reader.
In situ proximity ligation assays
In situ proximity ligation assays (PLAs) (Duolink kit, Olink Bioscience, Uppsala, Sweden) allows detection of direct or closely proximal protein-protein interactions in cell samples by fluorescence microscopy [65, 76] . THP-1/PMA cells were seeded, fixed and blocked as described above. Next samples were incubated simultaneously with mouse mAbs anti-β2 TS1/18, anti-αL TS1/11, anti-CD147 VJ1/9 or anti-CD81 5A6 mAbs, and with the anti-CD9 H-110 rabbit polyclonal antibody (sc-9148, Santa Cruz Biotechnology), followed by specific oligonucleotide-labeled secondary antibodies (anti-mouse-plus probe and anti-rabbit minus probe). Only if the two different target proteins are in close proximity (≤40 nm), the oligonucleotides of the two probes will hybridize and after a rolling-circle amplification reaction and detection with a different fluorescently labeled oligonucleotide a fluorescent dot signal can be visualized and analyzed by microscopy.
Statistical analysis
One-factor ANOVA analysis was performed using the statistics software SPSS (IBM). The data distribution was tested for normality by Bonferroni test. 
Results
CD9 associates with β2 integrin on the leukocyte surface
To investigate the possible association between CD9 and the β2 integrin LFA-1, we first studied the co-localization of these molecules by double immunofluorescence staining with specific mAbs and confocal microscopy analysis. We employed monocytic THP-1 cells because they constitutively display detectable surface expression of the three major β2 integrins (α L β 2 , α M β 2 α X β 2 ) and CD9 (Fig. 1A , upper histograms). Confirming previous reports, we observed that the surface expression of both CD9 [32, 50] and β2 integrins [1] was increased during PMA-induced differentiation of THP-1 cells into macrophagelike cells (Fig. 1A , lower histograms). As shown in Fig. 1B , CD9 and β2 integrin subunit were found to co-localize partially on the surface of undifferentiated monocytic THP-1 cells and this co-localization became much more evident on PMA-differentiated macrophage-like THP-1 (THP-1/PMA) cells, particularly at the cell-cell contact regions in the The GST and CD63-LEL-GST constructs were used as negative controls for specificity of binding. Formed complexes were pulled-down with glutathione-sepharose beads. For non-biotinylated cells, the presence of β2 integrin in the pulled-down complexes was revealed by immunoblotting with mAb MEM-48 (upper left-panel) and loading controls of GST fusion proteins stained with anti-GST polyclonal antibody are also shown (lower left-panel). For surface-biotinylated cells, all lysate proteins pulled-down by GST, CD63-LEL-GST or by CD9-LEL-GST were isolated with glutathione-sepharose beads and detected with streptavidin-HRP. As a control, β2 integrin was also immunoprecipitated with mAb TS1/18 from 1% Triton-X100 lysates of either surface-biotinylated or non-biotinylated (NB) JY cells and detected with streptavidin-HRP (which also clearly reveals the accompanying biotinylated 185 kDa band corresponding to the αL subunit of LFA-1) or by immunodetection with anti-β2 mAb MEM48, respectively. cellular aggregates that form during this differentiation process, as indicated by the increase in the Pearson co-localization coefficient. As we reported previously [55] , when activation of β2 integrin was induced with extracellular divalent cation Mn 2+ the localization of β2 integrin molecules changed from an evenly-distributed pattern to a patched/ clustered distribution and interestingly CD9 was clearly found colocalizing with clustered β2 integrin. Since the β2-specific mAb stained all the β2-containing integrins we also performed double immunofluorescence using an αL-specific mAb, confirming the pattern of colocalization between CD9 and LFA-1 (Fig. 1C) . The specificity of the co-localization between CD9 and LFA-1 was evidenced by the almost complete lack of co-localization observed between CD9 and CD147 ( Supplementary Fig. 1 ), which is another abundantly expressed surface protein on these cells (Fig. 1A) . Similar co-localization results were also observed in other leukocytes, including the B lymphoblastic JY and T leukemic Jurkat cells, which only express LFA-1, but not α M β 2 or α X β 2 ( Supplementary  Fig. 2 ), and collectively suggest that CD9 associates with β2-integrins, and particularly with LFA-1 (α L β 2 ), on the surface of different types of leukocytic cells.
To confirm the association of CD9 with LFA-1, coimmunoprecipitation experiments were performed using JY and THP-1/PMA cells. All immunoprecipitations were performed using intact cells that were incubated with the immunoprecipitating mAbs at 37°C prior to their lysis, thus ensuring that only interactions between cell surface molecules were detected. Immunoprecipitation using the β2-specific mAb TS1/18, from Brij-97 lysates of THP-1/PMA and JY cells, followed by immunoblotting with anti-CD9 mAb VJ1/20 clearly showed that this tetraspanin was co-precipitated with integrin LFA-1 ( Fig. 2A) . Co-immunoprecipitation was also detected in the reverse order, i.e. immunoprecipitating CD9 followed by immunodetection of β2 integrin (Fig. 2B) . Moreover, the association of LFA-1 with CD9 observed in Brij97-based lysates of THP-1/PMA and JY cells persisted under more stringent solubilization conditions such as the use of detergent Triton-X100 (1.0 %) (Fig. 3A) , thus pointing to a strong/direct type of interaction taking place between these molecules on the leukocyte surface. Similar results were also obtained using Triton-X100 (1.0 %) lysates of Jurkat cells (not shown). Parallel immunoprecipitations were also carried out with cells incubated with immunoprecipitating antibodies at 4°C and subsequently lysed in Triton-X100, to rule out that the observed association between CD9 and β2 integrin is caused by pre-incubation with antibodies at 37°C (Supplementary Fig. 3 ), and also with cells lysed at 4°C with this detergent prior to the addition of precipitating antibodies, yielding essentially the same results (data not shown).
When chemical crosslinking of solubilized proteins from JY cells was performed with thiol-cleavable DTSSP an important increase in the amount of CD9 co-immunoprecipitated with β2 integrin could be detected after cleavage of the cross-linked protein complexes in reducing conditions (Fig. 3B, left panel) . Essentially the same results were also obtained with THP-1/PMA cells (data not shown). Furthermore, immunoprecipitation with anti-β2 and anti-CD9 mAbs of non-cleaved crosslinked protein complexes resolved under non-reducing conditions clearly showed high molecular weight complexes of around 300 kDa which were immunodetected both with anti-β2 and anti-CD9 antibodies (Fig. 3B, right panel) , indicating that these molecules had been directly cross-linked. It is worth indicating that these~300 kDa bands are compatible with covalently cross-linked complexes containing both LFA-1 subunits (αL = 185 kDa; β2 = 95 kDa) plus a molecule of CD9 (24 kDa). Definitive proof that these~300 kDa bands correspond to complexes including CD9 and β2 integrin, was provided by the fact that they were immunoprecipitated both with anti-β2 and anti-CD9 antibodies, and immunodetected in both cases with an anti-β2 antibody (MEM-48) ( Supplementary Fig. 4 ). Taken together, these crosslinking experiments support a direct-type of interactions occurring between endogenous LFA-1 and CD9 in leukocytic cells.
Further support for the direct nature of CD9-LFA-1 interaction on the leukocyte surface was provided by in situ Proximity Ligation Assays (PLAs) on non-permeabilized THP1/PMA cells. PLA signal is only detected when the secondary probes directed against the two different molecules whose interaction is suspected are within a short range distance (b 40 nm) compatible with direct or closely proximal molecular interactions. As shown in Fig. 3C , PLA signal between CD9 and both subunits of LFA-1 (α L and β 2 ) was clearly revealed on the surface of THP-1/PMA cells, being the PLA signal particularly evident at cell-cell contact regions. The same procedure with the abundantly expressed membrane molecule CD147/EMMPRIN (Fig. 1A) did not provide any detectable PLA signal, revealing the specificity of PLA signal. As a positive control for primary/direct interactions, we assayed the association of CD9 with CD81, as these two tetraspanins are known to interact forming heterodimers and higher order oligomers on the cell surface [32, 43, 45] .
Most reported lateral interactions of tetraspanins with other proteins, and particularly with integrins, occur through the variable region of their Large Extracellular Loop (LEL) domain [34, 46, 67] . To assess whether CD9-LFA-1 interaction is mediated through this domain, we carried out pull-down assays employing a GST-fusion protein corresponding to the LEL domain of CD9 (CD9-LEL-GST) [29, 38] . The β2 subunit of endogenous LFA-1 was pulled down by CD9-LEL-GST from Brij-97 (not shown) and Triton-X100 (Fig. 3D, left panel) lysates of JY cells (and THP-1/PMA cells, not shown). As a positive control, another GST construct corresponding to the LEL domain of CD81, a tetraspanin closely related to CD9, also pulled-down the β2 integrin subunit, as previously reported [69] . In contrast, the GST-LEL construct of another tetraspanin, CD63, (CD63-LEL-GST) did not pull-down the β2 integrin subunit, reflecting the specificity of these LFA-1/tetraspanin interactions. Furthermore, the CD9-GST-LEL fusion protein selectively recovered both the β2 and the αL subunits of LFA-1 from a lysate of biotinlabeled JY cells, indicating that on these cells LFA-1 is a major surface protein that is selectively engaged in specific interactions with the LEL domain of CD9 (Fig. 3D, right panel) .
CD9 regulates the adhesive function of integrin LFA-1
We decided to explore whether CD9 could regulate the adhesive function of LFA-1. For this goal, we first assessed the effects of several CD9-specific mAbs (VJ1/20, PAINS-10 and PAINS-13), which exert an agonist-like action on CD9 [29, 31, 32, 51] , on LFA-1-mediated leukocyte adhesion. Treatment of THP-1/PMA cells with the three different anti-CD9 mAbs inhibited significantly their adhesion to immobilized ligand ICAM-1 (Fig. 4A, left panel) . The LFA-1-dependence of this assay was confirmed by the nearly complete inhibition of adhesion with the blocking anti-β2 mAb Lia3/2 and by the important stimulation of adhesion with the β2-activating mAb Kim185. Similar results were also obtained with B lymphoblastic JY cells, which do not express β1 integrin (Fig. 4B) .
In contrast to freshly isolated resting human lymphocytes, which express very little CD9 on their surface [5, 70] , PHA/IL-2-activated lymphocytes ("lymphoblasts") express abundantly the integrin LFA-1 as well as variable (from donor to donor) though consistently detectable levels of CD9 on their surface, together with modest α M β 2 and negligible α X β 2 integrin expression (Fig. 4C ). Using these primary human lymphoblasts in static adhesion assays on ligand ICAM-1, we observed essentially the same regulatory effects of CD9-specific mAbs on the adhesive activity of LFA-1 (Fig. 4D) , indicating that CD9 exerts inhibitory effects on LFA-1-mediated adhesion.
Interaction of integrin LFA-1 with specific ligands is a crucial step in many leukocyte intercellular interactions and particularly in the cytotoxic lymphocyte-mediated killing of target cells [2, 11, 24, 25, 40] . Interestingly, the observed inhibitory effect exerted by anti-CD9 mAbs (VJ1/20, PAINS-10 and PAINS-13) on LFA-1 was also reflected in LAK (lymphokine-activated killer cells)-mediated killing of target Daudi cells (Fig. 4E) . The allosterically inhibiting anti-CD18 mAb TS1/18 [57] was used as a blocking control. Taken together, these results confirm that mAbs with agonist-like effect on CD9 regulate negatively the adhesive function of LFA-1. We next wanted to address whether changes in the expression levels of CD9 could also regulate LFA-1 adhesiveness, either by ectopically expressing this tetraspanin in the CD9-deficient HSB-2 T lymphoblastic cell line or, conversely, by suppressing CD9 expression using shRNA interference in Jurkat T cells (Fig. 5A and B) . Ectopic expression of CD9 in HSB-2 cells reduced significantly LFA-1-mediated adhesion to immobilized ligand ICAM-1 (Fig. 5C) , whereas silencing CD9 in Jurkat cells enhanced LFA-1-mediated adhesion to ICAM-1 (Fig. 5D) . Interestingly, incubation of HSB-2/CD9 and Jurkat T cells with the anti-CD9 mAbs VJ1/20, PAINS-10 and PAINS-13, further reduced LFA-1-mediated adhesion to ICAM-1, confirming the agonist-like effect of these mAbs on CD9 function.
CD9-mediated regulation of LFA-1 adhesion does not involve changes in integrin affinity but alters its clustering
Integrin adhesive capacity is mainly regulated by two different mechanisms involving either, alterations in the conformation of individual integrin molecules that are reflected by affinity changes, or modifications in the aggregation of integrin molecules which affect the valency of their interactions with ligand. To investigate which of these mechanisms is involved in the observed CD9-mediated inhibition of LFA-1 adhesive function, we first analyzed the induction of expression of the m24 epitope by divalent cation Mn However, when T cell adhesion was promoted with phorbol ester PMA (at 50 and 200 ng/ml), which induces the intermediate affinity state of LFA-1 as well as ligand-dependent clustering of this integrin, CD9-caused inhibition of static adhesion was clearly observed even at the highest PMA dose (200 ng/ml) ( Fig. 7A and B) , suggesting that CD9 effect was somehow related to the aggregation/clustering of LFA-1. It is worth indicating that these CD9-caused inhibitory effects on adhesion are still maintained at higher concentrations of PMA (400 ng/ml) (data not shown), although cell viability under these conditions begins to be compromised. Importantly, these differences in PMA-induced LFA-mediated cell adhesion to ICAM-1 between T cells expressing or lacking CD9 were also consistently observed under flow conditions, therefore highlighting the relevance of CD9-mediated regulation of LFA-1 function under conditions that resemble a more physiological setting (Fig. 7C ).
To analyze in more detail the implication of CD9 in the organization of LFA-1 molecules, we first quantitated the number and size of LFA-1 clusters on the adhesive surface of PMA-stimulated T cells either expressing (JK TR2) or lacking CD9 (JK shCD9). As shown in Fig. 8A  (upper panel) , the number of PMA-induced LFA-1 clusters detected by confocal microscopy on the cellular adhesive surface in contact with immobilized ligand ICAM-1 was significantly higher on Jurkat T cells expressing CD9 than on their CD9-silenced counterparts. Interestingly, although fewer LFA-1 clusters were observed on cells lacking CD9 expression, their size was bigger than on CD9-expressing cells. Likewise, the presence of CD9 induced the organization of LFA-1 molecules into an increased number of smaller clusters in PMA-stimulated monocytic U937 cells adhering onto ICAM-1 (Fig. 8A, lower panel) . These results were corroborated by TIRF microscopy, which recognizes with high resolution and high signal-to-noise ratio the organization of cell surface molecules located specifically in the area of contact with the substrate (ICAM-1) . Quantitation of fluorescence from TIRF microscopy images shows that CD9-expressing T cells (JK TR2) display an increased number of clusters but of a smaller size as well as a significant proportion of LFA-1 molecules with a dispersed/unclustered appearance, compared to their CD9-lacking (JK shCD9) cell counterparts (Fig. 8B) .
As a complementary biochemical approach to get further insight on how CD9 affects the organization of LFA-1 molecules on the leukocyte surface, the differential resistance of LFA-1 molecules to extraction with increasing concentrations of detergent Triton X-100 (ranging from 0.02 to 1%) in Jurkat cells expressing (JK TR2) or lacking CD9 (JK shCD9) was analyzed. As shown in Fig. 8C , LFA-1 molecules were much more easily extracted when CD9 is expressed on the cell surface, as would be expected from the increased proportion of LFA-1 found in a dispersed/unclustered form and organized in smaller clusters.
Collectively, the confocal and TIRF microscopy data together with the biochemical extraction results show that CD9 affects the organization of LFA-1 molecules into clusters, as evidenced by the differences in the number and size of LFA-1 aggregates on the cell surface as well as by their resistance to detergent extraction.
Discussion
We report here that the β2 integrin LFA-1 associates with CD9 in different types of leukocytes, including T (Jurkat) and B (JY) lymphocytic cell lines, and PMA-differentiated THP-1 macrophage-like cells.
The CD9/LFA-1 association was evidenced by co-localization, in situ Proximity Ligation Assays (PLA), as well as biochemical studies based on co-immunoprecipitation, chemical cross-linking and pull-down assays. These interactions resist stringent cell solubilization conditions (i.e. 1% Triton X-100) in co-immunoprecipitation and pull-down experiments which, together with chemical cross-linking and PLA data, collectively support the direct nature of the interaction between CD9 and LFA-1. Both co-localization and PLA signal were particularly evident at the cell-cell contact regions of THP-1 cell aggregates formed during their PMA-induced differentiation process, which are areas enriched in LFA-1 molecules actively engaged in interactions with ICAM-1 ligand expressed on opposing cells, suggesting that the association of CD9 with LFA-1 might be important in the regulation of LFA-1 adhesive function. Tetraspanin-integrin interactions seem to be consistently mediated through the variable region of the LEL domain of tetraspanins [8, 20, 35, 79] ; in this regard our pull-down experiments with a recombinant construct corresponding to the CD9 LEL-domain indicate that the interaction between β2 integrin and CD9 is also mediated by this domain.
After demonstrating the existence of CD9-LFA-1 complexes in different types of leukocytes we next explored whether CD9 exerted any functional effects on the adhesive capacity of LFA-1. For this purpose, we have made use of three different anti-CD9 mAbs (VJ1/20, PAINS-10 and PAINS-13) considered to exert, at the cellular level, an agonist-like action on the basis that in different cellular systems the functional effects caused by treating CD9 + cells with these antibodies are similar to those derived from the neo-or over-expression of CD9, but opposite to those observed after silencing this tetraspanin [29, 32, 51] . The use of these three anti-CD9 mAbs, as well as ectopic expression of CD9 in HSB-2 T cells or silencing the endogenous CD9 expression in Jurkat T cells using specific shRNAs, collectively show that CD9 exerts a negative regulatory role on LFA-1-mediated leukocyte adhesion. Consistently with the CD9 inhibitory effect on adhesion, LAK-cellular cytotoxicity against target cells, which is largely dependent on LFA-1-mediated intercellular adhesion, was also inhibited by these anti-CD9 mAbs. Engagement of tetraspanins CD81 or CD82 with specific mAbs or overexpression of these molecules on T cells has been reported to upregulate the adhesive and signaling capacities of the integrin LFA-1 [62, 75] , whereas for the tetraspanin CD9 we report here the opposite: a clear inhibitory effect on LFA-1-mediated cellular adhesion and in vitro cellular cytotoxicity. One possibility is that the different functional effects of distinct tetraspanins on LFA-1 adhesive function might depend on the specific cellular system under study or the specific ligand employed (ICAM-3 employed in some of these previous reports versus ICAM-1 employed here), or alternatively CD9 may exert specific functional effects on LFA-1.
Integrin adhesive capacity can be regulated essentially by mechanisms involving either alterations in the affinity of individual integrin molecules or changes in their aggregation/clustering on the cell surface which regulate the valency of their interactions with ligand. As reported by the expression of the m24 epitope, the high affinity conformation of LFA-1 induced by Mn 2+ was not altered by ectopic expression or silencing of CD9; accordingly, no differences were observed in LFA-1-mediated adhesion stimulated by 400 μM Mn 2+ between cells expressing or lacking CD9. In contrast, it is interesting that at lower Mn 2+ concentrations (20 and 40 μM), at which presumably only a proportion of total LFA-1 molecules are in the high affinity conformation, differences in adhesion between cells expressing or lacking CD9 could be observed. Moreover, the differences between cells expressing and lacking CD9 were also consistently observed when cell adhesion was promoted with PMA, which induces the intermediate affinity state of LFA-1 as well as ligand-dependent clustering of this integrin. All these results clearly indicated that the effect of CD9 on LFA-1-mediated adhesion was mainly related to the aggregation/clustering state of this integrin and not to changes in its affinity. Indeed, confocal and TIRF microscopy analyses of PMA-induced LFA-1 clustering specifically at the adhesive cellular surface in contact with immobilized ligand ICAM-1 showed that in leukocytic cells expressing CD9 an increased number of clusters but with a smaller size could be detected in comparison with their CD9-lacking cell counterparts. TIRF microscopy images also revealed that in T cells expressing CD9 a significant proportion of LFA-1 molecules showed a dispersed/unclustered appearance, which might correspond to the nanoclusters of LFA-1 that have been characterized by other higher resolution microscopy techniques. In this regard, through the use of NSOM (near-field scanning optical microscopy) and SDT (single dye tracking) super-resolution optical techniques, it has been recently reported that LFA-1 is preorganized in nanoclusters in "hotspot" regions of the leukocyte membrane. Ligand binding favors the lateral mobility and growth of LFA-1 clusters through coalescence of individual nanoclusters to form microclusters, in a process that also critically depends on transient cytoskeleton anchorage, which in turn mediate efficient stable leukocyte adhesion under shear flow [3, 74] . Our findings are therefore compatible with these observations, and we can speculate that CD9 might have an important role in regulating these transitions among the different states of LFA-1 organization into distinct types of differently-sized clusters as well as the anchorage to the actin cytoskeleton. Interestingly, we have observed that the β1 integrin-mediated adhesion of leukocytes to the extracellular matrix protein fibronectin was enhanced by anti-CD9 mAbs or following ectopic expression of this tetraspanin (data not shown), which concurs with our previous data with colorectal carcinoma cells [51] . Therefore, CD9 seems to have a dual functional regulatory role on leukocyte adhesion mechanisms by increasing β1 adhesion to fibronectin but down-regulating LFA-1-mediated adhesion. Reciprocal control of the activity of members of distinct subfamilies of integrins co-expressed on the same cell has been previously described. For instance, in some leukemic T cell lines functionally active integrin α4β1 occurs only when LFA-1 is either not expressed or inactive [73] , whereas in human erythroleukemic K562 cells transfected with integrin αvβ3, ligation of the β3 integrin subunit inhibits the phagocytic function of endogenously expressed α5β1 integrin [12, 13] . Similarly, in human T lymphoblasts induction of activation of LFA-1 resulted in decreased adhesion through α4β1 and α5β1 integrins, rendering cells with a less adhesive and more migratory phenotype [52] . However, the underlying mechanisms for this type of regulation are still unclear. Association with cytoskeleton is essential for integrin activation and adhesion. Interestingly, actin cytoskeleton seems to play a differential role in the control of β1 and β2 integrin function. In this regard, in resting leukocytes LFA-1 molecules are maintained in an inactive low-avidity state through association with actin microfilaments and release from these cytoskeletal constraints, caused by drugs such as cytochalasin D or latrunculin B, increases their lateral diffusion which is accompanied by enhanced clustering and avidity and augmented LFA-1-mediated leukocyte adhesion to ICAM-expressing cells [44, 71] . In contrast, most β1 integrins (with the notable exception of α4β1 interaction with VCAM-1) mediate a more stable type of cell adhesion to extracellular matrix proteins such as fibronectin, collagen and laminin, and for this purpose seem to require firmer links with cytoskeletal components [10, 22, 59] . Several tetraspanins, including CD81 and CD9, are linked to actin microfilaments through ERM (Ezrin-Radixin-Moesin) proteins, either directly or through tetraspanin-associated partners EWI-2 and EWI-F [56] . The fact that CD9 may modulate in an opposite manner the adhesive function of β2 and β1 integrins points to CD9-centered TEMs as crucial players in this balanced regulation. An attractive possibility is that, by reinforcing the integrin-cytoskeletal links, CD9 may restrict the membrane lateral diffusion of LFA-1 molecules resulting in inhibition of its adhesive function, while at the same time, stabilizing β1 integrins with concomitant adhesion enhancement to matrix components. Further research will be required to properly address this attractive hypothesis.
The model depicted in Fig. 9 summarizes the main findings of this report. State "1" in the model is characterized by expression of dispersed and inactive/bent form of LFA-1 (Low-valency/Low-affinity) and by the absence/very low expression of CD9, as occurs physiologically in most resting/non-stimulated lymphocytes [5, 70] . Conversion from state "1" into a High-valency/Intermediate-affinity state ("2") is characterized by aggregation of integrin molecules into large clusters and the acquisition of intermediate affinity conformation, both induced by phorbol ester PMA. Within the context of TEMs, augmented CD9 function induced by its ectopic neoexpression (or by the use of agonist-like mAbs to this tetraspanin, not shown in the model), alters the organization of LFA-1 molecules at the cell adhesion surface, as evidenced by an increase in "dispersed" LFA-1 molecules and in the number of clusters with a reduced size, defining an Intermediate-valency/Intermediate-affinity state ("3") characterized by diminished adhesive efficiency to ligand ICAM-1 relative to state "2". On the other hand, state "4" is induced by high concentration of Mn 2+ and is characterized by clustering of LFA-1 molecules in a high affinity conformation (High-valency/ High-affinity state); in this case, transition from state "4" into "5", caused by the ectopic expression of CD9 (or by the use of agonist-like mAbs to this tetraspanin, not shown in the model), is not accompanied by a down-modulation of the adhesive efficiency because, although probably some reduction in the ligand-interaction valency occurs, this effect is not potent enough to decrease cell adhesion when mediated by a majority of LFA-1 molecules in the high affinity conformation. The inhibitory effects on LFA-1-mediated cell adhesion (observed in transitions "2"→"3") could place CD9 as a novel target for therapeutic intervention aimed at reducing the activity of LFA-1, which would be potentially beneficial in a number of inflammatory disorders.
Conclusions
Our data demonstrate that the tetraspanin CD9 associates with integrin LFA-1 in different types of leukocytes, and through these interactions, CD9 exerts inhibitory effects on LFA-1 adhesive function and leukocyte cytotoxic activity. The mechanism responsible for this negative modulation exerted by CD9 does not involve changes in the affinity state of LFA-1 but relates to alterations in its state of aggregation. These data contribute to our understanding of the regulation of adhesive activity of LFA-1, an integrin that plays a pivotal role in many crucial leukocyte functions that require intercellular adhesion. 
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